SCHEMBL3930787

SCHEMBL3930787

O=c1c(C2=CS(=O)(=O)c3cc(OCc4ccccc4)ccc3N2)c(O)c2cc(F)ccc2n1Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.43
NR1I2 O75469 1/20 0.40
EDNRB P24530 2/20 0.38
EDNRA P25101 2/20 0.38
MAOB P27338 5/20 0.37
MAOA P21397 3/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
RECQL P46063 1/20 0.37
CASP6 P55212 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PLK1 P53350 1/20 0.36
PTPN1 P18031 2/20 0.36
HDAC1 Q13547 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC11 Q96DB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4248241 0.90 CYP2C9 (0.48) CYP2C9NR1I2KDM4EHDAC1HDAC8
SCHEMBL3922130 0.88 PIK3R1 (0.44) CYP2C9NR1I2KDM4EPOLBHDAC1
SCHEMBL3920117 0.88 CYP2C9 (0.56) CYP2C9NR1I2KDM4EMEN1POLB
SCHEMBL3917989 0.87 CYP2C9 (0.42) CYP2C9NR1I2KDM4EMEN1ALDH1A1
SCHEMBL3920627 0.86 CYP2C9 (0.47) CYP2C9NR1I2KDM4EPLK1HDAC1
SCHEMBL3920019 0.86 CYP2C9 (0.50) CYP2C9NR1I2KDM4EMEN1ALDH1A1
SCHEMBL3919559 0.85 CYP2C9 (0.46) CYP2C9NR1I2KDM4EPLK1HDAC1
SCHEMBL3918627 0.85 CYP2C9 (0.46) CYP2C9NR1I2KDM4EHDAC1HDAC8
SCHEMBL3922914 0.85 CYP2C9 (0.39) CYP2C9NR1I2KDM4EMEN1KMT2A
SCHEMBL3929284 0.83 CYP2C9 (0.41) CYP2C9NR1I2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786807-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2009-07-29 EP claimed
US-7479489-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-01-20 US claimed
EP-1786807-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2007-05-23 EP claimed
WO-2006021340-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2006-03-02 WO claimed
US-20060040927-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-02-23 US claimed
EP-1786807-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2009-07-29 EP disclosed
US-7479489-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-01-20 US disclosed
EP-1786807-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2007-05-23 EP disclosed
WO-2006021340-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2006-03-02 WO disclosed
US-20060040927-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040927-A1 Heterocyclic antiviral compounds HAVCR2, POLR1A, HCCS CYP2C9 366/4885NR1I2 239/4885EDNRB 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.